Loading clinical trials...
Loading clinical trials...
A Phase II, Non Randomized, Open Label, Trial Evaluating Nilotinib as Treatment for Newly Diagnosed CML Patients in Accelerated Phase.
Conditions
Interventions
AMN107
Locations
18
Brazil
Novartis Investigative Site
Fortaleza, Ceará, Brazil
Novartis Investigative Site
Goiânia, Goiás, Brazil
Novartis Investigative Site
Cuiaba, Mato Grosso do Sul, Brazil
Novartis Investigative Site
Belo Horizonte, Minas Gerais, Brazil
Novartis Investigative Site
Curitiba, Paraná, Brazil
Novartis Investigative Site
Porto Alegre, Porto Alegre-RS, Brazil
Start Date
February 1, 2014
Primary Completion Date
January 1, 2017
Completion Date
January 1, 2017
Last Updated
April 20, 2017
NCT06514534
NCT05589896
NCT02790515
NCT03746054
NCT06865443
NCT01667133
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions